晚期碘难治性甲状腺癌的分子特征与仑伐替尼疗效
这项回顾性研究纳入49例接受一线仑伐替尼治疗的晚期碘难治性甲状腺癌患者,中位随访9.2年,采用二代测序检测组织基因变异。结果显示TERT突变最常见(57.1%),无任何突变者及TERT与驱动突变共存者对仑伐替尼反应较差,而单一驱动突变者无进展生存期更优。
要点
- TERT突变在晚期碘难治性甲状腺癌中最常见,占57.1%。
- 无任何突变者及TERT与驱动突变共存者对仑伐替尼反应较差。
- 存在单一驱动突变者无进展生存期更优。
核心结论
- RAIR-TC分子谱异质,TERT突变最常见,无突变者及TERT与驱动突变共存者对仑伐替尼反应更差。
- 存在单一驱动突变与更好的仑伐替尼反应相关。
研究设计与样本
- 回顾性研究,纳入49例接受一线仑伐替尼治疗并随访至少1年的RAIR-TC患者,中位随访9.2年(四分位距6-14.1)。
- 对组织进行二代测序检测基因变异。
主要发现
- BRAF突变占38.7%,RAS突变占22.4%,TERT突变占57.1%,TP53突变占6.1%。
- 无驱动突变者占34.6%,驱动突变与TERT或TP53共存者占44.9%,未发现任何突变者占20.4%(10/49)。
- BRAF突变和RAS突变者PFS和总生存期(OS)较好,但相对于野生型无统计学显著性。
临床怎么用
- 对晚期RAIR-TC患者可考虑进行分子检测,以识别可能从仑伐替尼治疗中获益更多或更少的亚群。
- 无任何突变或TERT与驱动突变共存的患者可能对仑伐替尼反应较差,需密切监测。
局限性
- 回顾性研究,样本量有限(49例),结果需前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The predictive role of mutational status in the response to lenvatinib in advanced radioiodine-refractory thyroid cancer (RAIR-TC) is not yet defined. OBJECTIVE: To identify a molecular signature of RAIR-TC treated with lenvatinib and its impact on clinical response to lenvatinib. DESIGN: This is a retrospective study including 49 RAIR-TC patients treated with first-line lenvatinib and followed at least 1 year [median follow-up 9.2 years (interquartile range 6-14.1)]. Next-generation sequencing on tissues was used to detect genetic alterations. SETTING: The study was performed in a referral center for the treatment of thyroid cancer. RESULTS: Among 49 cases, BRAF (38.7%) and RAS (22.4%) were the most frequent driver mutations, while TERT and TP53 were mutated in 57.1% and 6.1%. No driver mutations were found in 34.6%. Driver mutations co-occurred with TERT or TP53 in 44.9%. In 10/49 (20.4%), no mutations were found. Cases with ≥1 mutation had longer progression-free survival (PFS) than cases negative for any mutation (P = .004). Both BRAF-mutated and RAS-mutated cases showed better PFS and overall survival (OS), although this was not statistically significant with respect to wild-type cases. Cases with a single driver mutation (group 1) showed longer PFS than cases without driver mutations (group 3) (P = .04) but no difference with cases with driver + TERT or TP53 (group 2) (P = .13). Group 1 showed longer OS than group 2 (P = .026) and group 3 (P = .034). CONCLUSIONS: The RAIR-TC molecular profile is heterogeneous with TERT being the most frequent mutation. Cases negative for all mutations and cases presenting the coexistence of TERT + driver mutation had a worse response to lenvatinib. Conversely, the presence of 1 driver mutation correlated with a better response to lenvatinib.
引用
- Minaldi E, Ramone T, Ciampi R, et al. Molecular Profile of Advanced Radioiodine-refractory Thyroid Cancer and Response to Lenvatinib Treatment. J Clin Endocrinol Metab. 2026. PMID: 41891781. doi:10.1210/clinem/dgag074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。